Replies to post #13032 on GTC Biotherapeutics (fka GTCB)

[Lewis R Goudy]

Regardless of what you and Dr Meade chatted about the main
difference between CHO- and mammary-derived MAbs relevant
to enhanced ADCC is fucosylation, and the cited application
shows that aspect of GTC's comparative advantage over CHO
re ADCC is technologically at risk.

So mannose is a sugar, eh? Hmmm, mannose, fucose, dextrose,
glucose, sucrose...

I think I see a pattern here.